Migeotte, A.
Dufour, V.
van Maanen, A.
Berliere, M.
Canon, J. L.
Taylor, D.
Duhoux, F. P. http://orcid.org/0000-0002-5429-7888
Article History
Received: 24 April 2021
Accepted: 30 October 2021
First Online: 11 November 2021
Declarations
:
: The study was approved by the ethics committees of all participating hospitals and, as it is a retrospective study on pre-existing data, the informed consent was waived by these 3 same ethics committees, namely:- CUSL: Comité d’Ethique hospitalo-facultaire, ref. 2017/24JAN/041.- CMSE: Comité d’Ethique de la Clinique et Maternité Sainte-Elisabeth-Namur, ref. 03/17.- GHdC: Comité d’Ethique du Grand Hôpital de Charleroi, ref. G2–2017-E1.All methods were carried out in accordance with the Declaration of Helsinki and all relevant guidelines and regulations.
: Not applicable.
: FPD’s institution (CUSL) has received payments from the following pharmaceutical companies on his behalf: Amgen, AstraZeneca, Eli Lilly, Novartis, Pfizer, Roche and Teva. The other authors declare that they have no competing interests.